Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts

Protara Therapeutics, Inc. (NASDAQ:TARA) has been given an average rating of “Moderate Buy” by the seven research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $20.40.

TARA has been the topic of a number of research reports. Piper Sandler initiated coverage on shares of Protara Therapeutics in a research report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Wednesday, December 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Wednesday, October 8th.

Protara Therapeutics Stock Up 2.0%

Shares of TARA opened at $5.04 on Friday. The company has a market capitalization of $260.22 million, a price-to-earnings ratio of -3.52 and a beta of 1.42. Protara Therapeutics has a 52-week low of $2.77 and a 52-week high of $7.82. The stock has a 50 day moving average price of $5.79 and a 200 day moving average price of $4.47.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08. On average, equities analysts anticipate that Protara Therapeutics will post -3.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Protara Therapeutics

A number of large investors have recently bought and sold shares of TARA. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Protara Therapeutics in the second quarter valued at about $30,000. Quadrature Capital Ltd acquired a new stake in Protara Therapeutics in the second quarter valued at about $35,000. Almanack Investment Partners LLC. acquired a new stake in Protara Therapeutics in the third quarter valued at about $59,000. JPMorgan Chase & Co. purchased a new stake in Protara Therapeutics in the 2nd quarter valued at approximately $46,000. Finally, Los Angeles Capital Management LLC acquired a new position in Protara Therapeutics during the 2nd quarter worth approximately $47,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.